Human CD221/IGF1R HEK293T Stable Cell Line

Introduction

Human CD221/IGF1R HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and application of the insulin-like growth factor 1 receptor (IGF1R). This stable cell line is derived from the HEK293T cell line, a commonly used human embryonic kidney cell line, and has been genetically modified to stably express the human CD221/IGF1R gene. This cell line can be used in a variety of research applications, particularly in the field of cancer research.

Structure of Human CD221/IGF1R

The IGF1R is a transmembrane receptor protein that consists of two extracellular α-subunits and two transmembrane β-subunits. The α-subunits contain the ligand-binding domain, while the β-subunits contain the tyrosine kinase domain. The CD221/IGF1R gene encodes for a protein that is 1367 amino acids long and has a molecular weight of approximately 150 kDa. This stable cell line expresses the full-length CD221/IGF1R protein, allowing for the study of its structure and function.

Activity of Human CD221/IGF1R

The IGF1R plays a crucial role in cell growth, proliferation, and survival. It is activated by binding to its ligands, insulin-like growth factor 1 (IGF1) and insulin-like growth factor 2 (IGF2). Upon ligand binding, the α-subunits of the receptor undergo a conformational change, leading to the autophosphorylation of the β-subunits and the activation of the tyrosine kinase domain. This results in the activation of downstream signaling pathways, such as the PI3K-Akt and MAPK pathways, which regulate cell growth and survival.

The stable expression of CD221/IGF1R in HEK293T cells allows for the study of the receptor’s activity in a controlled environment. This cell line can be used to investigate the effects of various ligands, inhibitors, and mutations on the receptor’s activity. Additionally, the expression of the full-length CD221/IGF1R protein in this stable cell line ensures that the receptor is functional and can accurately reflect its activity in vivo.

Application of Human CD221/IGF1R HEK293T Stable Cell Line

The IGF1R is a promising therapeutic target in cancer treatment. Overexpression or dysregulation of this receptor has been observed in various types of cancer, including breast, lung, and prostate cancer. Inhibition of the IGF1R has been shown to decrease tumor growth and sensitize cancer cells to chemotherapy.

The Human CD221/IGF1R HEK293T Stable Cell Line can be used in drug discovery and development to screen for potential IGF1R inhibitors. This cell line can also be used in pre-clinical studies to evaluate the efficacy of IGF1R-targeted therapies. Furthermore, the stable expression of CD221/IGF1R in this cell line allows for the investigation of the mechanisms of resistance to IGF1R inhibitors, which is a common issue in cancer treatment.

Flow Cytometry Analysis

Flow cytometry is a powerful technique that allows for the quantitative analysis of cell surface proteins. The expression of CD221/IGF1R on the surface of HEK293T cells can be easily detected and quantified using flow cytometry. This technique can also be used to assess the effects of ligands, inhibitors, and mutations on the receptor’s expression and activity.

Conclusion

In summary, the Human CD221/IGF1R HEK293T Stable Cell Line is a valuable tool for studying the structure, activity, and application of the IGF1R. This stable cell line can be used in a variety of research applications, particularly in the field of cancer research.